Genetically engineered saccharomycetes for producing flavonoid glycoside compounds as well as construction method and application of genetically engineered saccharomycetes
By introducing naringin synthesis module and enzyme expression cassette in yeast, the de novo synthesis of vistin 2”-O-galactoside and citrustin 2”-O-galactoside in yeasts, the existing ones were solved by using the basic carbon source. The low efficiency and high cost of synthesis of flavonoid glycoside compounds in the technology have achieved an efficient and safe production process.
Patent Information
- Application Number
- CN202410981632.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-08
AI Technical Summary
The preparation method of flavonoid glycoside compounds in the prior art is inefficient and costly, especially the de novo synthesis efficiency of viscin and citrusin, and heterologous synthesis using basic carbon sources has not been achieved, which has safety and environmental pollution problems. .
Through genetic engineering, naringin synthesis module and related enzyme expression cassettes were introduced in yeasts, and viscein 2”-O-galactoside and yeast 2”-O-half were de novoked for synthesis of viscein 2”-O-half using basic carbon sources such as glucose and ethanol. Lactosin, achieving efficient production of whole cells.
It realizes efficient and safe synthesis of flavonoid glycoside compounds in yeasts, reduces production costs, simplifies the process flow, and avoids by-products and environmental pollution of chemical synthesis.
Smart Images

Figure BDA0004958259000000111 
Figure HDA0004958259250000011 
Figure HDA0004958259250000021
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology, and more specifically, relates to a genetically engineered yeast for producing flavonoid glycoside compounds, a construction method and an application thereof. Background Art
[0002] Trollius chinensis is a traditional medicinal plant with anti-inflammatory, antioxidant and antiviral effects. It is often used to treat upper respiratory tract infections, tonsillitis and otitis media. The main Chinese patent medicine preparations include Trollius chinensis granules, Trollius chinensis capsules and Trollius chinensis oral liquid. In addition, Trollius chinensis ingredients are also used in health products, skin care products and cosmetics. The main active chemical components in Trollius chinensis plants are flavonoid glycoside compounds, among which flavonoid carbon glycosides are the main ones, including vitexin, orientin, vitexin 2"-O-galactoside or orientin 2"-O-galactoside. Vitexin and orientin have good inhibitory activity against a variety of influenza viruses; they have the effect of inhibiting proliferation and inducing apoptosis of a variety of cancer cells; and they can reduce myocardial damage by activating the corresponding signaling pathways to exert antioxidant stress. Orientin 2”-O-galactoside and vitexin 2”-O-galactoside exert scavenging effects through several mechanisms, including hydrogen donation activity, inhibition of xanthine oxidase activity and superoxide anion production to protect cell membranes from lipid peroxidation, and have the potential to treat conditions such as brain dysfunction, liver disease and cancer.
[0003] At present, the main method for preparing flavonoid glycosides is still plant extraction, which is limited by the quality of raw materials and low efficiency. The extreme reaction conditions and toxic catalysts used in chemical synthesis methods will result in the safety of the production process and products cannot be guaranteed. The biosynthesis method is relatively mild, but there are not many cases that can achieve efficient synthesis of flavonoid glycosides from scratch.
[0004] The prokaryotic organism Escherichia coli has been used in the synthesis of vitexin and orientin, but it requires the addition of flavonoid precursor molecules, which leads to high costs. Even if de novo synthesis is performed, the synthesis of vitexin and orientin is still inefficient. Moreover, the current heterologous de novo synthesis of vitexin 2"-O-galactoside and orientin 2"-O-galactoside using basic carbon sources has not yet been achieved.
[0005] Therefore, this field urgently needs to further research and develop new chassis hosts and production processes for vitexin, orientin, vitexin 2"-O-galactoside and orientin 2"-O-galactoside, in order to achieve efficient synthesis, simplify operations and reduce costs in terms of process. Summary of the invention
[0006] The purpose of the present invention is to provide a genetically engineered yeast for producing flavonoid glycoside compounds, a construction method and application thereof. The technical solution of the present invention is currently the only technical solution that can synthesize vitexin 2"-O-galactoside or orientin 2"-O-galactoside from scratch in whole cells from basic carbon sources such as glucose and ethanol.
[0007] In a first aspect of the present invention, a method for producing flavonoid glycoside compounds (flavonoid carbon glycoside compounds) is provided, comprising: providing a yeast engineering bacterium, introducing a naringenin synthesis module into the yeast engineering bacterium to synthesize naringenin; and further comprising:
[0008] (a) introducing the expression cassette of the following enzymes: FNSI, F3'H, CPR1, CGT1, so as to synthesize orientin using naringenin as a precursor; or
[0009] (b) Introducing the expression cassettes of the following enzymes: FNSI, CGT1, thereby synthesizing vitexin using naringenin as a precursor.
[0010] In one or more embodiments, (a) further comprises an expression cassette for introducing the following enzymes: GAL10, OGT4, so as to synthesize orientin 2″-O-galactoside using orientin as a precursor.
[0011] In one or more embodiments, (b) further comprises an expression cassette for introducing the following enzymes: GAL10, OGT4, so as to synthesize vitexin 2″-O-galactoside using vitexin as a precursor.
[0012] In one or more embodiments, the naringenin synthesis module includes expression cassettes of the following enzymes: TAL, 4CL, CHS, CHI.
[0013] In one or more embodiments, the introduction is exogenous introduction or heterologous introduction.
[0014] In one or more embodiments, the enzyme comprises a heterologous enzyme relative to the engineered yeast.
[0015] In one or more embodiments, when the expression cassette of the enzyme is introduced into the yeast engineering bacteria, the TAL+4CL+CHS+CHI expression cassette, the FNSI+CGT1 expression cassette, and the F3'H+CPR1 expression cassette are introduced to obtain the orientin production strain.
[0016] In one or more embodiments, when the expression cassette of the enzyme is introduced into the yeast engineering bacteria, the TAL+4CL+CHS+CHI expression cassette, the FNSI+CGT1 expression cassette, and the F3'H+CPR1+GAL10+OGT4 expression cassette are introduced to obtain the orientin 2"-O-galactoside production strain.
[0017] In one or more embodiments, when the expression cassette of the enzyme is introduced into the yeast engineering bacteria, the TAL+4CL+CHS+CHI expression cassette and the FNSI+CGT1 expression cassette are introduced to obtain a vitexin-producing strain.
[0018] In one or more embodiments, when the expression cassette of the enzyme is introduced into the yeast engineering bacteria, the TAL+4CL+CHS+CHI expression cassette, the FNSI+CGT1 expression cassette, and the GAL10+OGT4 expression cassette are introduced to obtain a vitexin 2"-O-galactoside production strain.
[0019] In one or more embodiments, the gene combination is placed in one or more expression constructs. For example, the gene fragments of TAL+4CL+CHS+CHI, the gene fragments of FNSI+CGT1, and the gene fragments of F3'H+CPR1+GAL10+OGT4 are placed in separate constructs.
[0020] In one or more embodiments, the yeast engineered bacteria are cultured using a yeast culture medium, and preferably a carbon source is added during the culture period; preferably, the carbon source is glucose and / or ethanol.
[0021] In one or more embodiments, when producing vitexin, orientin, vitexin 2"-O-galactoside or orientin 2"-O-galactoside, no precursor amino acids and / or flavonoids and / or malonyl-CoA and / or UDP-glucose are added.
[0022] In one or more embodiments, glucose is added once every 12 to 36 hours to a final concentration of 1 to 4% (v / v); or ethanol is added once every 12 to 36 hours to a final concentration of 0.5 to 2% (v / v).
[0023] In one or more embodiments, glucose and ethanol are added once every 12 to 36 hours, with glucose added to a final concentration of 1 to 4% (v / v) and ethanol added to a final concentration of 0.5 to 2% (v / v).
[0024] In one or more embodiments, the fermentation process is divided into a batch stage and a feeding stage, wherein the early stage of the feeding stage is glucose feeding (flow addition), and the middle and late stages are ethanol feeding.
[0025] In one or more embodiments, fermentation dissolved oxygen is maintained between 20-50% (v / v).
[0026] In one or more embodiments, the pH of the fermentation broth is maintained at 5.0-7.0.
[0027] In one or more embodiments, glucose is used as a carbon source to promote bacterial growth in the early stage of fermentation, and glucose is continuously provided as a feed until the bacteria grow to 200±50g / L (preferably 200±30g / L, 200±20g / L or 200±10g / L) wet weight; then, ethanol is switched to feed, and preferably, the flow rate is gradually increased from 2ml / L / h to 12ml / L / h.
[0028] In one or more embodiments, when producing vitexin, orientin, vitexin 2"-O-galactoside or orientin 2"-O-galactoside, the culture time is 60 to 200 hours.
[0029] In one or more embodiments, the yeast culture medium is YPD, YPE or YPDE medium.
[0030] In one or more embodiments, BSM is used as the basal medium.
[0031] In one or more embodiments, the culture temperature is 30±2°C, more preferably 30±1°C.
[0032] In one or more embodiments, the rotation speed during shake flask culture is 200±50 r / min, more preferably 200±20 r / min.
[0033] In one or more embodiments, during large-scale fermentation, the stirring speed in the fermentation tank is 500-2000 r / min; preferably 800-1200 r / min.
[0034] In one or more embodiments, when producing vitexin, orientin, vitexin 2"-O-galactoside or orientin 2"-O-galactoside, the culture time is 80 to 180 hours, more preferably 130 to 160 hours, such as 140, 144, 150, 155 hours.
[0035] In one or more embodiments, the culture is continued for 120±40 hours, preferably the fermentation is completed after 120±30 hours, 120±20 hours or 120±10 hours.
[0036] In another aspect of the present invention, a yeast engineered bacterium for producing flavonoid glycoside compounds is provided, wherein the yeast engineered bacterium comprises a naringenin synthesis module and an expression cassette selected from (a) or (b):
[0037] (a) an expression cassette of the following enzymes: FNSI, F3'H, CPR1, CGT1, wherein the expression cassette uses naringenin as a precursor to synthesize orientin; or
[0038] (b) Expression cassettes of the following enzymes: FNSI, CGT1, which synthesize vitexin using naringenin as a precursor.
[0039] In one or more embodiments, (a) further includes expression cassettes of the following enzymes: GAL10, OGT4, and the expression cassettes use orientin as a precursor to synthesize orientin 2"-O-galactoside.
[0040] In one or more embodiments, (b) further includes expression cassettes of the following enzymes: GAL10, OGT4, and the expression cassettes use vitexin as a precursor to synthesize vitexin 2"-O-galactoside.
[0041] In one or more embodiments, the naringenin synthesis module includes expression cassettes of the following enzymes: TAL, 4CL, CHS, CHI.
[0042] In one or more embodiments, the GAL10 is from Saccharomyces cerevisiae (Sc).
[0043] In one or more embodiments, the OGT4 and CGT1 are from Trollius chinensis (Tc).
[0044] In one or more embodiments, the F3'H is from rice (Oryza sativa; Os).
[0045] In one or more embodiments, the CPR1 is from Aspergillus terreus (At).
[0046] In one or more embodiments, the FNSI is derived from parsley (Petroselinum crispum; Pc).
[0047] In one or more embodiments, the TAL is from Flavobacterium johnsoniaeu (Fj).
[0048] In one or more embodiments, the 4CL, CHS, and CHI are derived from Scutellaria baicalensis Georgi (Sb).
[0049] In one or more embodiments, the engineered yeast used to produce vitexin contains an exogenous expression cassette of the following genes: TAL, 4CL, CHS, CHI, FNSI, and CGT1.
[0050] In one or more embodiments, the yeast engineered bacteria used to produce vitexin 2″-O-galactoside contain exogenous expression cassettes of the following genes: TAL, 4CL, CHS, CHI, FNSI, CGT1, GAL10, and OGT4.
[0051] In one or more embodiments, the yeast engineered bacteria used to produce orientin contain exogenous expression cassettes of the following genes: TAL, 4CL, CHS, CHI, FNSI, F3'H, CPR1, and CGT1.
[0052] In another aspect of the present invention, an expression cassette containing the following exogenous genes: TAL, 4CL, CHS, CHI, FNSI, F3'H, CPR1, CGT1, GAL10, OGT4 is provided in a yeast engineered bacterium for producing orientin 2"-O-galactoside.
[0053] In one or more embodiments, the engineered yeast bacteria include Pichia pastoris.
[0054] In one or more embodiments, the engineered yeast bacteria includes Pichia pastoris GS115.
[0055] In one or more embodiments, the gene encoding the TAL enzyme has the nucleotide sequence shown in SEQ ID NO:1, or a degenerate sequence thereof, or a nucleotide sequence encoding a protein with the same function that is more than 70% (preferably more than 80%; more preferably more than 90%; more preferably more than 93%; more preferably more than 95%; more preferably more than 97%) identical to the sequence of SEQ ID NO:1.
[0056] In one or more embodiments, the gene encoding the 4CL enzyme has the nucleotide sequence shown in SEQ ID NO:2, or a degenerate sequence thereof, or a nucleotide sequence encoding a protein with the same function that is more than 70% (preferably more than 80%; more preferably more than 90%; more preferably more than 93%; more preferably more than 95%; more preferably more than 97%) identical to the sequence of SEQ ID NO:2.
[0057] In one or more embodiments, the gene encoding the CHS enzyme has the nucleotide sequence shown in SEQ ID NO:3, or a degenerate sequence thereof, or a nucleotide sequence encoding a protein with the same function that is more than 70% (preferably more than 80%; more preferably more than 90%; more preferably more than 93%; more preferably more than 95%; more preferably more than 97%) identical to the sequence of SEQ ID NO:3.
[0058] In one or more embodiments, the gene encoding the CHI enzyme has the nucleotide sequence shown in SEQ ID NO:4, or a degenerate sequence thereof, or a nucleotide sequence encoding a protein with the same function that is more than 70% (preferably more than 80%; more preferably more than 90%; more preferably more than 93%; more preferably more than 95%; more preferably more than 97%) identical to the sequence of SEQ ID NO:4.
[0059] In one or more embodiments, the gene encoding the FNSI enzyme has the nucleotide sequence shown in SEQ ID NO:5, or a degenerate sequence thereof, or a nucleotide sequence encoding a protein with the same function that is more than 70% (preferably more than 80%; more preferably more than 90%; more preferably more than 93%; more preferably more than 95%; more preferably more than 97%) identical to the sequence of SEQ ID NO:5.
[0060] In one or more embodiments, the gene encoding the F3'H enzyme has the nucleotide sequence shown in SEQ ID NO:6, or a degenerate sequence thereof, or a nucleotide sequence encoding a protein with the same function that is more than 70% (preferably more than 80%; more preferably more than 90%; more preferably more than 93%; more preferably more than 95%; more preferably more than 97%) identical to the sequence of SEQ ID NO:6.
[0061] In one or more embodiments, the gene encoding the CPR1 enzyme has the nucleotide sequence shown in SEQ ID NO:7, or a degenerate sequence thereof, or a nucleotide sequence encoding a protein with the same function that is more than 70% (preferably more than 80%; more preferably more than 90%; more preferably more than 93%; more preferably more than 95%; more preferably more than 97%) identical to the sequence of SEQ ID NO:7.
[0062] In one or more embodiments, the gene encoding the CGT1 enzyme has the nucleotide sequence shown in SEQ ID NO:8, or a degenerate sequence thereof, or a nucleotide sequence encoding a protein with the same function that is more than 70% (preferably more than 80%; more preferably more than 90%; more preferably more than 93%; more preferably more than 95%; more preferably more than 97%) identical to the sequence of SEQ ID NO:8.
[0063] In one or more embodiments, the gene encoding the GAL10 enzyme has the nucleotide sequence shown in SEQ ID NO:9, or a degenerate sequence thereof, or a nucleotide sequence encoding a protein with the same function that is more than 70% (preferably more than 80%; more preferably more than 90%; more preferably more than 93%; more preferably more than 95%; more preferably more than 97%) identical to the sequence of SEQ ID NO:9.
[0064] In one or more embodiments, the gene encoding the OGT4 enzyme has the nucleotide sequence shown in SEQ ID NO: 10, or a degenerate sequence thereof, or a nucleotide sequence encoding a protein with the same function that is more than 70% (preferably more than 80%; more preferably more than 90%; more preferably more than 93%; more preferably more than 95%; more preferably more than 97%) identical to the sequence of SEQ ID NO: 10.
[0065] In another aspect of the present invention, a method for adding (in a condensation manner) a sugar group (galactoside) to the sugar group of vitexin or orientin is provided, comprising: using vitexin or orientin as a precursor, and using two enzymes, GAL10 and OGT4, to catalyze the reaction, thereby allowing vitexin to form vitexin 2"-O-galactoside, or allowing orientin to form orientin 2"-O-galactoside.
[0066] In another aspect of the present invention, a use of a gene combination is provided for producing or modifying flavonoid glycoside compounds; wherein the gene combination is gene combination a, which is a combination of GAL10 and OGT4, and is used to add (in a condensed manner) a sugar group (galactoside) to the sugar group of vitexin or orientin; preferably, the gene combination a causes vitexin to form vitexin 2"-O-galactoside, or causes orientin to form orientin 2"-O-galactoside.
[0067] In another aspect of the present invention, a use of a gene combination is provided for producing or modifying flavonoid glycoside compounds; wherein the gene combination is gene combination b, which includes a combination of FNSI, F3'H, CPR1 and CGT1, and is used to synthesize orientin using naringenin as a precursor; or a combination thereof includes TAL, 4CL, CHS, CHI, FNSI, F3'H, CPR1 and CGT1, and is used to synthesize orientin from scratch;
[0068] Or, the gene combination is gene combination c, which is a combination of FNSI and CGT1, used to synthesize vitexin using naringenin as a precursor; or a combination thereof including TAL, 4CL, CHS, CHI, FNSI and CGT1, used to synthesize vitexin from scratch;
[0069] Or, the gene combination is gene combination d, which is a combination of FNSI, F3'H, CPR1, CGT1, GAL10 and OGT4, and is used to synthesize orientin 2"-O-galactoside using naringenin as a precursor; or a combination of TAL, 4CL, CHS, CHI, FNSI, F3'H, CPR1, CGT1, GAL10 and OGT4, and is used to synthesize orientin 2"-O-galactoside from scratch;
[0070] Or, the gene combination is gene combination e, which is a combination of FNSI, CGT1, GAL10 and OGT4, and is used to synthesize vitexin 2″-O-galactoside using naringenin as a precursor; or a combination thereof including TAL, 4CL, CHS, CHI, FNSI, CGT1, GAL10 and OGT4, and is used to synthesize vitexin 2″-O-galactoside from scratch.
[0071] In one or more embodiments, each gene of the gene combination is constructed independently or in combination into an expression cassette, or into an expression construct (such as an expression vector).
[0072] In another aspect of the present invention, a kit for producing or modifying flavonoid glycoside compounds is provided, comprising: the engineered yeast bacteria.
[0073] In another aspect of the present invention, a kit for producing or modifying flavonoid glycoside compounds is provided, comprising: one or more gene combinations defined above; preferably, the gene combination is contained in an expression cassette or expression construct (such as an expression vector).
[0074] In one or more embodiments, the kit further includes: glucose and / or ethanol.
[0075] Other aspects of the present invention will be apparent to those skilled in the art in view of the disclosure herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0076] Figure 1 , vitexin, orientin, vitexin 2”-O-galactoside and the synthetic pathway of orientin 2”-O-galactoside.
[0077] Figure 2 , shake flask fermentation diagram of the strain producing vitexin, orientin, vitexin 2”-O-galactoside and orientin 2”-O-galactoside.
[0078] Figure 3 , 3L reactor fermentation diagram of the strain producing vitexin 2”-O-galactoside.
[0079] Figure 4 , 3L reactor fermentation diagram of the strain producing orientin 2”-O-galactoside. DETAILED DESCRIPTION
[0080] After in-depth research, the inventors introduced a series of exogenous genes into yeast engineering strains through gene recombination technology to obtain yeast engineering bacteria that can produce flavonoid glycoside compounds (including vitexin, orientin, vitexin 2"-O-galactoside and / or orientin 2"-O-galactoside). The engineering bacteria for producing flavonoid glycoside compounds obtained by the present invention have the characteristics of low metabolic background, strong heterologous expression ability, no need to add precursors (such as amino acids, flavonoids, malonyl coenzyme A and UDP-glucose), whole-cell synthesis of final products, and easy separation of final products, etc., which provides a new way for the industrial production of flavonoid glycoside drugs.
[0081] the term
[0082] As used herein, the "expression cassette" or "gene expression cassette" refers to a gene expression system that contains all the necessary elements required to express the target polypeptide, which generally includes the following elements: a promoter, a gene sequence encoding a polypeptide, and a terminator; in addition, it may optionally include a signal peptide coding sequence, etc.; these elements are operably linked.
[0083] As used herein, the term "operably linked" or "operably linked" refers to the functional spatial arrangement of two or more nucleic acid regions or nucleic acid sequences. For example, a promoter region is placed at a specific position relative to the target gene nucleic acid sequence, so that transcription of the nucleic acid sequence is guided by the promoter region, and thus the promoter region is "operably linked" to the nucleic acid sequence.
[0084] As used herein, the "expression construct" or "expression construct" refers to a recombinant DNA molecule that contains a desired nucleic acid coding sequence, which may contain one or more gene expression cassettes. The "construct" is usually contained in an expression vector.
[0085] As used herein, the term "exogenous" or "heterologous" refers to the relationship between two or more nucleic acid or protein sequences from different sources, or the relationship between a protein (or nucleic acid) and a host cell from different sources. For example, a nucleic acid is exogenous to a host cell if the combination of nucleic acid and host cell does not normally occur in nature. A particular sequence is "exogenous" to a cell or organism into which it is inserted.
[0086] As used herein, the "flavonoid glycoside compounds" may also be referred to as "vitex compounds", including vitexin, orientin, vitexin 2"-O-galactoside or orientin 2"-O-galactoside. The "flavonoid glycoside compounds" may also be variations of the compounds disclosed in the present invention, for example, the parent core structure of the compound remains unchanged, but a group (such as an aliphatic hydrocarbon group containing 1-4 carbon atoms (preferably 1-2 carbon atoms)) is substituted at individual (such as 1-3, 1-2) positions.
[0087] Production system overview
[0088] Although there have been some studies in the field on the synthesis of vitexin and orientin by the prokaryotic organism Escherichia coli, the production requires the addition of additional flavonoid precursor molecules, resulting in high costs. In the case of de novo synthesis, the expression activity of the E. coli host is low, the production efficiency of flavonoid glycosides is low, and the production capacity is extremely limited, far from the industrial level. The selection or expression of heterologous functional enzymes may be one of its bottlenecks. In order to achieve expression in E. coli, some studies in this field adopt a reaction method of opening the compound and then regulating the reaction environment to close the loop, but this is not only cumbersome, but also reduces the reaction efficiency.
[0089] Although the expression of eukaryotic yeast has been studied and applied in the art, for some flavonoid glycosides such as vitexin and orientin, the synthesis efficiency of Saccharomyces cerevisiae is still very low even if the metabolic engineering of Saccharomyces cerevisiae has been rationally modified. As for Pichia pastoris, it is often used in protein expression and some production in the art, but there is no precedent in the art for successfully applying it to the efficient production of flavonoid glycosides such as vitexin and orientin.
[0090] The present invention changes the status of the art and provides a genetically engineered yeast for producing flavonoid glycoside compounds. By heterologously expressing the following enzymes in the yeast engineered bacteria: tyrosine ammonia lyase (TAL), p-coumaroyl-CoA ligase (4CL), chalcone synthase (CHS), chalcone isomerase (CHI), flavone synthase (FNSI), C-glucosyltransferase (CGT1), the de novo synthesis of vitexin in yeast cells is achieved. Further, by integrating glucose 4-isomerase (GAL10) and O-galactosyltransferase (OGT4) on the basis of the strain, de novo synthesis of vitexin 2″-O-galactoside can be achieved in yeast cells. Or further, by integrating flavone 3′-hydroxylase (F3′H) and cytochrome P450 reductase (CPR1) on the basis of the strain, de novo synthesis of orientin in yeast cells can be achieved. Or further, by integrating F3′H, CPR1, GAL10 and OGT4 on the basis of the strain, de novo synthesis of orientin 2″-O-galactoside can be achieved in yeast cells. The synthetic pathway of the product of the present invention is as follows Figure 1 .
[0091] The present invention realizes for the first time that microorganisms use basic carbon sources to synthesize vitexin 2"-O-galactoside and orientin 2"-O-galactoside from scratch.
[0092] The recombinant yeast engineered bacteria constructed in the present invention have good compatibility with the preferred plant enzyme / microbial enzyme of the present invention, and have unique advantages over the prokaryotic organism Escherichia coli in heterologous expression. Good expression and catalytic activity are obtained without modification of the enzyme structure, and flavonoid glycoside compounds are efficiently produced.
[0093] Genes and their expression systems
[0094] The technical solution of the present invention can realize the synthesis of a variety of flavonoid glycoside compounds, and the flavonoid glycoside compounds include vitexin, orientin, vitexin 2"-O-galactoside and orientin 2"-O-galactoside.
[0095] In a preferred embodiment of the present invention, the efficient production of vitexin or vitexin 2"-O-galactoside in yeast engineering bacteria is achieved by transforming the yeast engineering bacteria into a six-gene combination (TAL, 4CL, CHS, CHI, FNSI, CGT1) or an eight-gene combination 1 (TAL, 4CL, CHS, CHI, FNSI, CGT1, GAL10, OGT4); the efficient production of orientin or orientin 2"-O-galactoside in yeast engineering bacteria is achieved by transforming the yeast engineering bacteria into an eight-gene combination 2 (TAL, 4CL, CHS, CHI, FNSI, F3'H, CPR1, CGT1) or a ten-gene combination (TAL, 4CL, CHS, CHI, FNSI, F3'H, CPR1, CGT1, GAL10, OGT4). In a preferred embodiment of the present invention, the six-gene combination includes the following genes: TAL, 4CL, CHS, CHI, FNSI, CGT1; the eight-gene combination 1 includes the following genes: TAL, 4CL, CHS, CHI, FNSI, CGT1, GAL10, OGT4; the eight-gene combination 2 includes the following genes: TAL, 4CL, CHS, CHI, FNSI, F3'H, CPR1, CGT1; the ten-gene combination includes the following genes: TAL, 4CL, CHS, CHI, FNSI, F3'H, CPR1, CGT1, GAL10, OGT4. The inventors have successfully achieved the co-expression of these heterologous genes in yeast cells and the high-activity production of compounds.
[0096] The gene of the present invention may be naturally occurring, such as being isolated or purified from plants or microorganisms. In addition, the gene may also be artificially prepared, such as being obtained according to conventional genetic engineering recombination techniques, or being obtained by an artificial synthesis method.
[0097] The nucleotide sequence of the above-mentioned gene may be the same as the sequence shown in SEQ ID NO: 1 to 10, or it may be a degenerate variant thereof. As used herein, "degenerate variant" in the present invention refers to a nucleic acid sequence that encodes a protein with the same function but is different from the sequence selected from SEQ ID NO: 1 to 10. The present invention includes the natural sequence of the above-mentioned gene, and also includes the sequence after codon optimization. In the present invention, the natural gene sequence is currently used for recombinant expression. It can be expected that the yield can be further improved by optimizing using some codon optimization methods known in the art and establishing optimized yeast engineering bacteria. These further optimization techniques based on the scheme of the present invention should also be included in the technical scheme of the present invention.
[0098] The gene may include: a coding sequence encoding only a mature polypeptide; a coding sequence of a mature polypeptide and various additional coding sequences; a coding sequence of a mature polypeptide (and optional additional coding sequences) and non-coding sequences.
[0099] The present invention also relates to variants of the gene, wherein the polypeptide encoded by the gene is different from the corresponding wild-type polypeptide in amino acid sequence and is a fragment, analog or derivative of the wild-type polypeptide. The variant of the polynucleotide may be a naturally occurring allelic variant or a non-naturally occurring variant. These nucleotide variants include substitution variants, deletion variants and insertion variants. As known in the art, an allelic variant is an alternative form of a polynucleotide, which may be a substitution, deletion or insertion of one or more nucleotides, but will not substantially change the function of the polypeptide encoded by it.
[0100] The present invention also relates to polynucleotides that hybridize with the above-mentioned sequences and have at least 50%, preferably at least 70%, and more preferably at least 80% identity between the two sequences. The present invention particularly relates to polynucleotides that can hybridize with the polynucleotides of the present invention under stringent conditions. In the present invention, "stringent conditions" refer to: (1) hybridization and elution at relatively low ionic strength and relatively high temperature, such as 0.2×SSC, 0.1% SDS, 60°C; or (2) the addition of denaturants during hybridization, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% Ficoll, 42°C, etc.; or (3) hybridization occurs only when the identity between the two sequences is at least 90%, preferably at least 95%. In addition, the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the corresponding wild-type polypeptide.
[0101] Each gene of the present invention is preferably obtained from Flavobacterium johnsonii, scutellaria, parsley, rice, Aspergillus terreus, nasturtium and Saccharomyces cerevisiae. The present invention may also include other genes obtained from other microorganisms that are highly homologous (e.g., having more than 70%, such as 80%, 90%, 95%, or even 98% sequence identity) to the corresponding genes in Flavobacterium johnsonii, scutellaria, parsley, rice, Aspergillus terreus, nasturtium and Saccharomyces cerevisiae, and are also within the scope of the present invention. Methods and tools for comparing sequence identity are also well known in the art, such as BLAST.
[0102] The full-length sequence of each gene of the present invention or its fragments can usually be obtained by PCR amplification, recombination or artificial synthesis. For PCR amplification, primers can be designed based on the relevant nucleotide sequence disclosed in the present invention, especially the open reading frame sequence, and the relevant sequence can be amplified. When the sequence is long, PCR amplification can be performed twice or more, and then the fragments amplified in each time are spliced together in the correct order.
[0103] The present invention also relates to a vector comprising the polynucleotide, and a host cell produced by genetic engineering using the vector.
[0104] In the present invention, the sequence of each gene can be inserted into a recombinant expression vector. The term "recombinant expression vector" refers to bacterial plasmids, bacteriophages, yeast plasmids, plant cell viruses, mammalian cell viruses or other vectors well known in the art. In short, any plasmid and vector can be used as long as they can replicate and be stable in the host. An important feature of an expression vector is that it usually contains a replication origin, a promoter, a marker gene and a translation control element.
[0105] The sequence of each gene can be inserted into a recombinant expression vector respectively, and multiple recombinant expression vectors can be co-transfected into a host cell; the expression cassettes of multiple genes can also be inserted into the same recombinant expression vector in a tandem manner and transferred into a host cell. The recombinant expression vector may also contain an expression control sequence operably connected to the sequence of the gene to facilitate the expression of the protein. It should be understood that after those skilled in the art understand the technical content of the present invention, they can conveniently construct a recombinant expression vector. The obtained recombinant expression vector is also included in the present invention.
[0106] In the expression regulatory sequence or expression cassette, an inducible or constitutive promoter can be used according to different needs. The inducible promoter can achieve more controllable protein expression and compound production, which is conducive to industrial application.
[0107] As a preferred embodiment of the present invention, an expression vector (expression construct) is provided, which includes expression cassettes of the following genes: TAL, 4CL, CHS, CHI, FNSI, F3'H, CPR1, CGT1, GAL10, OGT4.
[0108] The establishment of expression vectors (expression constructs) can adopt the techniques familiar to those skilled in the art. After knowing the desired selected gene, those skilled in the art can establish expression constructs. The gene sequence can be inserted into different expression constructs (such as expression vectors) or into the same expression construct, as long as the encoded polypeptide can be effectively expressed and active after being transferred into cells. As a preferred embodiment of the present invention, the expression vector is pGAP Zα.
[0109] The vector containing the above-mentioned appropriate gene sequence and appropriate promoter or control sequence can be used to transform appropriate host cells to enable them to express proteins. In the present invention, the host cell is preferably an engineered yeast, more preferably Pichia pastoris, such as Pichia pastoris GS115.
[0110] Transformation of host cells with recombinant DNA can be carried out using conventional techniques well known to those skilled in the art. When the host is a eukaryote, the following DNA transformation methods can be selected: calcium phosphate coprecipitation, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.
[0111] The obtained transformants can be cultured by conventional methods, and the medium used in the culture can be a yeast medium well known in the art, and the culture is carried out under conditions suitable for the growth of yeast cells.
[0112] The present invention also provides a kit for biosynthesis of flavonoid glycosides, which includes: TAL, 4CL, CHS, CHI, FNSI and CGT1 genes or expression constructs (including expression plasmids) or yeast cells containing the genes; or includes: TAL, 4CL, CHS, CHI, FNSI, CGT1, GAL10 and OGT4 genes or expression constructs (including expression plasmids) or yeast cells containing the genes; or includes: TAL, 4CL, CHS, CHI, FNSI, F3'H, CPR1 and CGT1 genes or expression constructs (including expression plasmids) or yeast cells containing the genes; or includes: TAL, 4CL, CHS, CHI, FNSI, F3'H, CPR1, CGT1, GAL10 and OGT4 genes or expression constructs (including expression plasmids) or yeast cells containing the genes. More preferably, the kit also includes instructions for use describing the method of biosynthesis.
[0113] The recombinant Pichia pastoris strain obtained by the gene recombination technology of the present invention has the characteristics of low metabolic background, strong heterologous expression ability, no need to add additional precursors, whole-cell synthesis of the final product, and easy separation of the final product. It will largely solve the problems existing in the synthesis of traditional biological and chemical methods and provide a new way for the industrial production of flavonoid glycosides.
[0114] Method for synthesizing flavonoid glycosides
[0115] In the present invention, the flavonoid glycoside compounds include vitexin, orientin, vitexin 2"-O-galactoside and orientin 2"-O-galactoside.
[0116] The structural formula of vitexin is shown in the following formula (I), the structural formula of orientin is shown in the following formula (II), the structural formula of vitexin 2"-O-galactoside is shown in the following formula (III), and the structural formula of orientin 2"-O-galactoside is shown in the following formula (IV).
[0117]
[0118] The invention discloses a method for producing vitexin, orientin, vitexin 2"-O-galactoside and orientin 2"-O-galactoside by heterologous synthesis using microorganisms. The method comprises: transforming six genes (preferably TAL, 4CL, CHS, CHI, FNSI, CGT1) into yeast engineering bacteria to produce vitexin; or, transforming eight genes (preferably TAL, 4CL, CHS, CHI, FNSI, CGT1, GAL10, OGT4) into yeast engineering bacteria to produce vitexin 2"-O-galactoside; or, transforming eight genes (preferably TAL, 4CL, CHS, CHI, FNSI, F3'H, CPR1, CGT1) into yeast engineering bacteria to produce orientin; or, transforming ten genes (preferably TAL, 4CL, CHS, CHI, FNSI, F3'H, CPR1, CGT1, GAL10, OGT4) into yeast engineering bacteria to produce orientin 2"-O-galactoside.
[0119] The present invention also provides a fermentation and culture method of a recombinant yeast engineered bacterium for producing vitexin, orientin, vitexin 2"-O-galactoside or orientin 2"-O-galactoside. The yeast engineered bacterium for producing vitexin, orientin, vitexin 2"-O-galactoside or orientin 2"-O-galactoside of the present invention can be cultured using a yeast culture medium, preferably with a carbon source added during the culture period; preferably, the carbon source is glucose and / or ethanol; preferably, glucose and / or ethanol are added once every 12 to 36 hours; more preferably, glucose is added to a final concentration of 1 to 4% (v / v), and ethanol is added to a final concentration of 0.5 to 2% (v / v). It is particularly noteworthy that the recombinant yeast engineering bacteria of the present invention have ideal enzyme activity and mobilize the endogenous mechanism of yeast cells during production. Therefore, the technical solution of the present invention can produce flavonoid glycosides without adding precursor amino acids and / or flavonoids and / or malonyl coenzyme A and / or UDP-glucose; this is conducive to large-scale production on the one hand, and simplifies the process (for example, the preparation of the culture medium is simpler and clearer, and the separation and purification of the later products is more convenient) and reduces costs on the other hand. In a preferred embodiment of the present invention, the inventors optimized the culture time to 100 to 200 hours, preferably 120 to 180 hours, and more preferably 130 to 160 hours based on the production characteristics of the recombinant yeast engineering bacteria for producing vitexin, orientin, vitexin 2"-O-galactoside or orientin 2"-O-galactoside.
[0120] In a specific embodiment of the present invention, a preferred method for producing vitexin, orientin, vitexin 2"-O-galactoside or orientin 2"-O-galactoside is provided, comprising: culturing the recombinant bacteria to the logarithmic phase in a liquid YPD culture at 30°C and a rotation speed of 200 r / min, collecting the bacteria, washing them twice with sterile water, and then transferring them to YPD, YPE or YPDE culture medium, and culturing them at 30°C and a rotation speed of 200 r / min for 120 hours. During the fermentation process, 2% glucose and / or 0.5% ethanol are added to the liquid culture medium every 24 hours.
[0121] After obtaining the fermentation product, vitexin, orientin, vitexin 2"-O-galactoside or orientin 2"-O-galactoside can be extracted from the fermentation product using the known technology of the present invention. High performance liquid chromatography can be used to analyze and identify the product to determine that the desired compound is obtained.
[0122] Reagent test kit
[0123] The present invention also provides a kit comprising an engineered strain for producing the flavonoid glycoside compound. In addition, it may also include a culture medium for yeast cells and a reagent for separating or detecting the flavonoid glycoside compound. More preferably, the kit may also include instructions for use for describing the method for biosynthesizing the flavonoid glycoside compound.
[0124] The present invention also provides a kit for constructing the engineering strain producing flavonoid glycoside compounds, and the kit may include a series of constructs, for example, the constructs provided in the embodiments of the present invention may be referenced, or other constructs containing the genes but with different gene arrangements or tandem connections. The establishment of expression vectors (expression constructs) may adopt techniques familiar to those skilled in the art. After knowing the enzymes required to be selected and the cell systems required to be expressed, those skilled in the art may establish expression constructs. The gene sequence may be inserted into different expression constructs (such as expression vectors) or into the same expression construct, as long as the encoded polypeptide can be effectively expressed and active after being transferred into cells. The kit may also include yeast cells, culture medium of yeast cells, and separation or detection reagents for the flavonoid glycoside compounds. More preferably, the kit may also include instructions for use of the method for biosynthesizing flavonoid glycoside compounds, etc.
[0125] The main points of the present invention are:
[0126] The present invention uses recombinant Pichia pastoris to heterologously produce vitexin, orientin, vitexin 2"-O-galactoside and orientin 2"-O-galactoside, which not only solves the problems of plant extraction method consuming a large amount of plant raw materials, being restricted by seasonal and regional factors, and having low extraction efficiency; it also avoids the unfavorable factors of chemical synthesis method such as many by-products, low activity of target products, and great environmental pollution, and opens up a new way for the industrial production of flavonoid glycosides such as vitexin. Therefore, the recombinant Pichia pastoris strain of the present invention has the potential for industrial production of vitexin, orientin, vitexin 2"-O-galactoside and orientin 2"-O-galactoside.
[0127] The present invention achieves a technical breakthrough in the whole-cell de novo biosynthesis of vitexin, orientin, vitexin 2"-O-galactoside and orientin 2"-O-galactoside using recombinant yeast, and does not require the addition of amino acids or flavonoids or malonyl-CoA or UDP-glucose precursors. For the first time, it is achieved that the basic carbon sources such as glucose and ethanol can be used to meet the efficient production requirements of vitexin, orientin, vitexin 2"-O-galactoside and orientin 2"-O-galactoside, providing a new approach for the production of vitexin and other flavonoid glycoside compounds.
[0128] The present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually carried out according to conventional conditions such as those described in J. Sambrook et al., Molecular Cloning Experiment Guide, 3rd edition, Science Press, 2002, or according to the conditions recommended by the manufacturer.
[0129] Culture medium
[0130] YPD liquid medium: glucose 20.0 g / L, peptone 20.0 g / L, yeast extract 10.0 g / L.
[0131] YPE liquid culture medium: ethanol 5 ml / L, peptone 20.0 g / L, yeast extract 10.0 g / L.
[0132] YPDE liquid culture medium: glucose 20.0 g / L, ethanol 5 ml / L, peptone 20.0 g / L, yeast extract 10.0 g / L.
[0133] YPD solid medium: glucose 20.0 g / L, peptone 20.0 g / L, yeast extract 10.0 g / L, agar 20.0 g / L.
[0134] YND solid medium: glucose 20.0 g / L, amino-free yeast nitrogen base (YNB) 6.7 g / L, agar 20.0 g / L.
[0135] Example 1. Construction of expression plasmid
[0136] 1. Genetic information and P GAP Construction of plasmids expressing each gene
[0137] The genes involved are shown in Table 1.
[0138] Table 1
[0139] Gene source sequence TAL Flavobacterium johnsoniaeu (Fj) SEQ ID NO:1 4CL Scutellaria baicalensis Georgi (Sb) SEQ ID NO:2 CHS Scutellaria baicalensis Georgi (Sb) SEQ ID NO:3 CHI Scutellaria baicalensis Georgi (Sb) SEQ ID NO:4 FNSI Parsley (Petroselinum crispum; PC) SEQ ID NO:5 F3'H Rice (Oryza sativa; Os) SEQ ID NO:6 CPR1 Aspergillus terreus (At) SEQ ID NO:7 CGT1 Golden Lotus (Trollius chinensis; Tc) SEQ ID NO:8 GAL10 Saccharomyces cerevisiae (Sc) SEQ ID NO:9 OGT4 Golden Lotus (Trollius chinensis; Tc) SEQ ID NO:10
[0140] Genes FjTAL, Sb4CL, SbCHS, SbCHI, PcFNSI, OsF3'H, AtCPR1, TcCGT1, ScGAL10, and TcOGT4 were fully synthesized by Nanjing GenScript Biotechnology Co., Ltd. and directly constructed on the vector plasmid pGAP Zα (Invitrogen).
[0141] The names of the obtained plasmids are: pGAP_FjTAL, pGAP_Sb4CL, pGAP_SbCHS, pGAP_SbCHI, pGAP_PcFNSI, pGAP_OsF3'H, pGAP_AtCPR1, pGAP_TcCGT1, pGAP_ScGAL10, pGAP_TcOGT4.
[0142] 2. Construction of gene combination plasmid
[0143] The plasmids pGAP_FjTAL, pGAP_PcFNSI, pGAP_OsF3'H and pGAP_ScGAL10 constructed in "1" were digested with BamH I, and the linearized plasmids were recovered respectively.
[0144] The plasmids pGAP_Sb4CL, pGAP_TcCGT1, pGAP_AtCPR1 and pGAP_-TcOGT4 constructed in the previous "1" were used as templates, and the complete expression cassettes of Sb4CL, TcCGT1, AtCPR1 and TcOGT4 genes including promoters and terminators were recovered by PCR amplification (primers SEQ ID NO: 11, 12). The linearized plasmids and gene expression cassettes can be connected by seamless assembly kit to obtain plasmids pGAP_FjTAL+Sb4CL, pGAP_PcFNSI+TcCGT1, pGAP_OsF3'H+AtCPR1, pGAP_ScGAL10+TcOGT4.
[0145] The plasmids pGAP_FjTAL+Sb4CL and pGAP_OsF3'H+AtCPR1 were digested with BamH I to recover the linearized plasmids. The plasmids pGAP_SbCHS and pGAP_ScGAL10 constructed in the previous "1" were used as templates, and the complete expression cassettes of the SbCHS and ScGAL10 genes including the promoter and terminator were recovered by PCR amplification (primers SEQ ID NO: 12, 13). The linearized plasmids and gene expression cassettes can be connected by a seamless assembly kit to obtain plasmids pGAP_FjTAL+Sb4CL+SbCHS and pGAP_OsF3'H+AtCPR1+ScGAL10.
[0146] The plasmids pGAP_FjTAL+Sb4CL+SbCHS and pGAP_OsF3'H+AtCPR1+ScGAL10 were digested with BamH I to recover the linearized plasmids. The plasmids pGAP_SbCHI and pGAP_TcOGT4 constructed in the previous "1" were used as templates, and the complete expression cassettes of the SbCHI and TcOGT4 genes including the promoter and terminator were recovered by PCR amplification (primer SEQ ID NO: 12, 13). The linearized plasmids and gene expression cassettes can be connected by a seamless assembly kit to obtain plasmids pGAP_FjTAL+Sb4CL+SbCHS+SbCHI and pGAP_OsF3'H+AtCPR1+ScGAL10+TcOGT4.
[0147] 3. Construction of gene combination plasmid containing homology arms
[0148] Plasmids pDAg2, pDTg1 and pDFg1 (see Liu Q, Shi X, Song L, et al. CRISPR–Cas9 mediated genomic multilociintegration in Pichia pastoris [J]. Microbial Cell Factories, 2019, 18: 144) were double-digested with ApaI and XhoI to recover the linearized plasmids. Using the plasmids pGAP_FjTAL+Sb4CL+SbCHS+SbCHI, pGAP_PcFNSI+TcCGT1, pGAP_OsF3'H+AtCPR1+ScGAL10+TcOGT4, pGAP_OsF3'H+AtCPR1, and pGAP_ScGAL10+TcOGT4 constructed in "2" as templates, fragments containing multiple gene expression cassettes were obtained by PCR amplification (primers SEQ ID NO: 14-15). The linearized plasmid and the gene expression cassette fragments were connected by a seamless assembly kit to obtain the following plasmids:
[0149] pDAg2_FjTAL+Sb4CL+SbCHS+SbCHI;
[0150] pDTg1_PcFNSI+TcCGT1;
[0151] pDFg1_OsF3'H+AtCPR1+ScGAL10+TcOGT4;
[0152] pDFg1_OsF3′H+AtCPR1;
[0153] pDFg1_ScGAL10+TcOGT4.
[0154] Example 2: Preparation of target recombinant yeast
[0155] 1. PCR verification of recombinant strains
[0156] Each DNA fragment and the corresponding gRNA plasmid were electroporated into Pichia pastoris (GS115). After recovery, the DNA fragments were spread on YND solid medium. After 5 days of culture, fresh colonies were picked and cultured in YPD liquid medium. The genome of each transformant was extracted using a yeast genome extraction kit, and the integration of each gene for vitexin synthesis into the Pichia pastoris genome was identified by cloning PCR reaction.
[0157] Cloning PCR reaction conditions:
[0158] (1) Initial denaturation at 95°C for 5 min;
[0159] (2) denaturation at 95°C for 30 s, annealing at 50°C for 30 s, and extension at 72°C for 1 min / kb, for 30 cycles;
[0160] (3) Final extension at 72°C for 7 min.
[0161] 2. Obtaining a vitexin-producing strain containing six exogenous genes
[0162] Using plasmids pDAg2_FjTAL+Sb4CL+SbCHS+SbCHI and pDTg1_PcFNSI+TcCGT1 as templates, each gene fragment containing homology arms was obtained by PCR amplification, and the circular plasmid 3.5k-PAg2+PTg1 (primers and circular plasmids are all referred to Liu Q, Shi X, Song L, et al. CRISPR-Cas9 mediated genomic multilociintegration in Pichia pastoris [J]. Microbial Cell Factories, 2019, 18: 144) was simultaneously electrotransformed into Pichia pastoris competent cells, and recombinants were screened using YND solid culture to obtain Pichia pastoris genetic engineering bacteria transformed with 6 exogenous genes (FjTAL, Sb4CL, SbCHS, SbCHI, PcFNSI, TcCGT1). The strain was streaked on YPD solid medium, and the recombinant strain was verified by PCR again to ensure that the circular plasmid was lost.
[0163] 3. Obtaining a strain producing vitexin 2"-O-galactoside containing 8 exogenous genes
[0164] Using plasmids pDAg2_FjTAL+Sb4CL+SbCHS+SbCHI, pDTg1_PcFNSI+TcCGT1, and pDFg1_ScGAL10+TcOGT4 as templates, each gene fragment containing the homologous arm was obtained by PCR amplification, and was simultaneously electroporated into Pichia pastoris competent cells with the circular plasmid 3.5k-PFg1+PAg2+PTg1 (primers and circular plasmids are referred to Liu Q et al. CRISPR-Cas9mediated genomic multilociintegration in Pichia pastoris [J]. Microbial Cell Factories, 2019, 18: 144). Recombinants were screened using YND solid culture to obtain Pichia pastoris genetically engineered bacteria transformed with 8 exogenous genes (FjTAL, Sb4CL, SbCHS, SbCHI, PcFNSI, TcCGT1, ScGAL10, TcOGT4). The strain was streaked onto YPD solid medium, and PCR verification of the recombinant strain was performed again to ensure the loss of the circular plasmid.
[0165] 4. Obtaining a strain producing orientin containing 8 exogenous genes
[0166] Using plasmids pDAg2_FjTAL+Sb4CL+SbCHS+SbCHI, pDTg1_PcFNSI+TcCGT1, and pDFg1_OsF3'H+AtCPR1 as templates, each gene fragment containing homology arms was obtained by PCR amplification, and the circular plasmid 3.5k-PFg1+PAg2+PTg1 (primers and circular plasmids were used as described above) was electrotransformed into Pichia pastoris competent cells at the same time, and recombinants were screened using YND solid culture to obtain Pichia pastoris genetic engineering bacteria transformed with 8 exogenous genes (FjTAL, Sb4CL, SbCHS, SbCHI, PcFNSI, OsF3'H, AtCPR1, and TcCGT1). The strain was streaked on YPD solid culture medium, and the recombinant strain was verified by PCR again to ensure that the circular plasmid was lost.
[0167] 5. Obtaining a strain producing orientin 2"-O-galactoside containing 10 exogenous genes
[0168] Using plasmids pDAg2_FjTAL+Sb4CL+SbCHS+SbCHI, pDTg1_PcFNSI+TcCGT1, and pDFg1_OsF3'H+AtCPR1+ScGAL10+TcOGT4 as templates, each gene fragment containing homology arms was obtained by PCR amplification, and the circular plasmid 3.5k-PFg1+PAg2+PTg1 (primers and circular plasmids were used as described above) was electrotransformed into Pichia pastoris competent cells at the same time, and recombinants were screened using YND solid culture to obtain Pichia pastoris genetic engineering bacteria transformed with 10 exogenous genes (FjTAL, Sb4CL, SbCHS, SbCHI, PcFNSI, OsF3'H, AtCPR1, TcCGT1, ScGAL10, and TcOGT4). The strain was streaked on YPD solid culture medium, and the recombinant strain was verified by PCR again to ensure that the circular plasmid was lost.
[0169] Example 3: Fermentation process of recombinant engineering bacteria in 250 ml conical flask
[0170] The strain producing vitexin contains 6 exogenous genes: FjTAL, Sb4CL, SbCHS, SbCHI, PcFNSI, and TcCGT1.
[0171] A strain producing vitexin 2"-O-galactoside: containing 8 exogenous genes: FjTAL, Sb4CL, SbCHS, SbCHI, PcFNSI, TcCGT1, ScGAL10, and TcOGT4.
[0172] The strain producing orientin contains 8 exogenous genes: FjTAL, Sb4CL, SbCHS, SbCHI, PcFNSI, OsF3'H, AtCPR1, and TcCGT1.
[0173] A strain producing orientin 2"-O-galactoside: containing 10 exogenous genes: FjTAL, Sb4CL, SbCHS, SbCHI, PcFNSI, OsF3'H, AtCPR1, TcCGT1, ScGAL10, and TcOGT4.
[0174] The recombinant bacteria were cultured in liquid YPD medium at 30°C and 200 r / min to the logarithmic phase, and the cells were collected, washed twice with sterile water, and transferred to a 250 mL conical flask containing 50 mL YPD liquid medium and cultured at 30°C and 200 r / min for 120 h. During the fermentation process, 2% (v / v) glucose was added to the liquid medium every 24 h.
[0175] Example 4, 3L reactor fermentation process
[0176] The basal medium BSM (the formula has been commercialized by Invitrogen) was used as the culture medium. The fermentation process was divided into a batch stage and a fed-batch stage. The early stage of the fed-batch stage was glucose feeding (flow addition), and the middle and late stages were ethanol feeding.
[0177] During the period, the stirring speed in the fermentation tank is controlled at 1000r / min; oxygen is provided to ensure that the dissolved oxygen in the fermentation is maintained between 20-50%; and ammonia water is provided to ensure that the pH of the fermentation liquid is maintained between 5.0-7.0.
[0178] In the early stage of fermentation, glucose was used as the carbon source to promote bacterial growth. Glucose was continuously provided as feed until the bacteria grew to 200 g / L wet weight. Then, ethanol was used as feed. The flow rate was gradually increased from 2 ml / L / h to 12 ml / L / h. The fermentation was terminated after 120 hours of cultivation.
[0179] Example 5: Extraction and identification of fermentation products of recombinant strains
[0180] The recombinant strains verified above were cultured in YPD liquid medium until the logarithmic phase, and 50OD (Note: OD value is yeast concentration unit, 1OD is approximately 5x10 7 Yeast cells. OD value was measured by UV spectrophotometer at 600nm wavelength) The cells were washed twice with sterile water and transferred into 50mL YPD liquid medium. The culture temperature was 30℃ and the speed was 200r / min for 120h. After fermentation, 1mL of the fermentation broth was added with an equal volume of methanol and mixed thoroughly, and centrifuged at 12000g for 2min. The supernatant was filtered and used for high performance liquid chromatography (HPLC) analysis.
[0181] The HPLC analysis was performed by reverse HPLC Agilent 1100, using a C18 column, a column temperature of 30°C, an ultraviolet detection wavelength of 335 nm, 100% acetonitrile for phase A, and 0.1% formic acid for phase B. The elution method was: 0-12 min, 16% phase A; 12-30 min, 16%-100% phase A; 30-34 min, 100% phase A; 34-36 min, 100%-16% phase A; 36-41 min, 16% phase A.
[0182] Example 6. Cell biomass and product yield during fermentation
[0183] 1. Fermentation culture in conical flask
[0184] Fermentation was carried out according to the 250 ml conical flask fermentation culture method of Example 3. Samples were taken 120 hours after fermentation to measure the cell biomass and the product amounts of vitexin, orientin, vitexin 2"-O-galactoside and orientin 2"-O-galactoside.
[0185] The growth and production of strains are shown in Figure 2 . After 120h of fermentation, the production of vitexin was 359.5mg / L, the production of orientin was 280.4mg / L, the production of vitexin 2”-O-galactoside was 843.6mg / L, and the production of orientin 2”-O-galactoside was 480.4mg / L. This is the highest yield of vitexin and orientin synthesized from scratch by whole cells so far, and it is also the first time that vitexin 2”-O-galactoside or orientin 2”-O-galactoside has been synthesized from scratch by whole cells. In addition, there is no need to add amino acids or flavonoids or malonyl-CoA or UDP-glucose as precursors during fermentation. Only basic carbon source glucose is needed to meet production requirements.
[0186] 2. 3L reactor fermentation culture
[0187] Fermentation was carried out according to the fermentation culture method of the 3 L reactor of Example 4. Samples were taken at 24 h, 72 h, and 120 h of fermentation to determine the wet weight of the cells and the amount of vitexin 2"-O-galactoside or orientin 2"-O-galactoside product.
[0188] The fermentation and production conditions of the strains producing vitexin 2"-O-galactoside or orientin 2"-O-galactoside are shown in Figure 3 and 4 . With the increase of fermentation time, the cell biomass and product amount of the two strains gradually increased. After 120 hours of fermentation, the production of vitexin 2"-O-galactoside reached 8587.7 mg / L, and the production of orientin 2"-O-galactoside reached 5093.9 mg / L. This is the first time that whole-cell de novo synthesis of vitexin 2"-O-galactoside or orientin 2"-O-galactoside has been achieved, and there is no need to add amino acids or flavonoids or malonyl-CoA or UDP-glucose as precursors during fermentation. Only basic carbon sources such as glucose or ethanol are needed to meet production requirements.
[0189] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims. At the same time, all the documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference separately.
[0190] Sequence information
[0191] SEQ ID NO: 1 (FjTAL, Flavobacterium johnsonii, DNA):
[0192] atgaatacgattaacgagtacctttctttggaggagtttgaggccataattttcgggaatcagaaggtcactatatcagatgtcgttgtgaatcgcgtaaatgagtcgtttaac
[0193] tttctgaaggagttttcgggtaacaaagtcatctatggggtgaacacggggtttggtccaatggcgcagtaccgtatcaaggaatcggaccaaattcaattgcaatataac
[0194] ctaattcggagccactcaagcgggacaggtaaacctcttagtcctgtatgtgctaaagccgctatccttgcccggctaaatacactcagtctaggtaattctggcgtacatc
[0195] cgagtgttataaaccttatgtcagagttgataaataaggacattacacctctgatctttgaacatggcggcgttggcgcgagcggtgacctagtccaattatcacacctggc
[0196] gcttgttcttataggggaaggagaagtattctataaaggagaacgtcgtcctacgccagaagtgtttgaaattgaagggctaaagccaatccaggttgagattcgagagg
[0197] gactagcactgatcaatggtacctccgttatgacaggtatcggcgtcgttaacgtgtaccatgcgaagaagttgctggactggtccctcaagtctagttgcgcaataaacg
[0198] agttagtacaggcttacgatgatcactttagtgctgaactcaatcaaaccaagcgtcataagggacaacaggagatcgctctgaaaatgaggcagaatctctcagattcta
[0199] cgttgattagaaagcgagaagatcacctctactccggtgagaatacggaggaaattttcaaagaaaaggtgcaggaatattattccctaaggtgtgtgccacagattctag
[0200] gccccgtattggaaactattaataatgtagcaagcattcttgaggatgaatttaattccgccaacgacaatccgattatcgatgtgaagaaccaacatgtgtatcacggggg
[0201] caactttcatggcgactatatctcgttagagatggacaaattgaaaattgtcattaccaaacttactatgttagcggaacgccaattaaattacttattaaattctaaaatcaac
[0202] gaattactgccccccttcgtgaatctcggaactttgggttttaactttggaatgcagggagttcaattcacagcaacttctactaccgcggaatctcagatgctttctaacccg
[0203] atgtacgtgcattcgataccgaacaataacgataatcaagacatagtcagcatgggtaccaactcagccgtaattacttctaaagtaatagagaatgcttttgaagttctgg
[0204] ccatcgaaatgatcacaatagtccaggcaatcgattacctgggacaaaaggataaaatatcttcggtcagcaaaaaatggtacgatgagattagaaacataatacctacg
[0205] tttaaagaggaccaagttatgtatcccttcgtacagaaggtcaaggaccacctcataaataactga
[0206] SEQ ID NO:2 (Sb4CL, Scutellaria baicalensis, DNA):
[0207] atggaaactgttgagaatcatggtgatgttatttttagatctaaattgcctgatatatacattccaaaacatttgccattgcactcttattgctttgaaaacatttcagaacataga
[0208] actaaaccatgtttgattaatggtgctactaatgaagttcatacttatgaagaagttgaattgatttctagaaaaagttgctgctggtttgtctcatttgggtttgcatcatggtgat
[0209] actattatgatttgttgccaaattctcctgaatttgtttttgcttttttgggtgcttcttatattggtgctgtttctactatggctaatccatttttttactcctgctgaagtaatcaaaca
[0210] agctaaggcatctaatgctaaattaatcattactcaagcttgttatgttaaaaaagtttgggattatgctgttgaaaatggtgttagagttatgtgtgttgattctccaccacctg
[0211] aagctgctggtgaatgtttggaattttctcaattgacttctgctgatgaaggtgatatgcctgaagttgaaattaattctgaagatgttgttgctttgccatattcttctggtacta
[0212] ctggtttgccaaaaggtgttatgttgactcataaaggtttggttacttctgttgctcaacaagttgatggtgaaaatccaaatttgtatattcactctgatgatgtcattttgtgtgt
[0213] tttaccattgttccacatctactctttaaattctgttttgttgtgtggtttgagagttggtgctgccattttaattatgcaaaaatttgatattgtgccattcttggaactcattcaaag
[0214] atataaagttactattggtccatttgttccaccaattgttttggctattgttaaatctcctgttgttggtaattatgatttatcttctattagaactgttatgtctggtgctgctccattg
[0215] ggtaaagaattggaagaagctgttagaattaaatttccaaatgctaaattgggtcaaggttatggtatgactgaagctggtcctgttttggctatgtgtttggcttttgctaaag
[0216] aaaaaaaaaatgaaattaaatctggtgcttgtggtactgttgttagaaatgctgaaatgaaaattgttgatattgaaactgctgcttctttgggtagaaatcaacctggtgaaatttgt
[0217] attagaggtgatcaaattatgaaaggttatttgaatgatcctgaatctactgctagaactattgataaagaaggttggttgcatactggtgatattggttttattgatgatgatga
[0218] tgagttgttcattgttgatagattgaaggaaatcattaaatataaaggttttcaagttgctcctgctgaaattgaagctttgttgttgaatcatccatctatttctgatgctgctgtt
[0219] gtttctatgaaagatgaagagctggtgaagtgcctgttgcttttgttgtgaaatctaatggttctactattactgaggatgatatcaaacagtttatcagtaaacaagttattttt
[0220] tataaaaaatccatagggttttttttattgatgctattccaaaaaacccatctggtaaaattttgagaaaagatttgagagctattttgccaactaaagctgctactttgtctaat
[0221] tga
[0222] SEQ ID NO:3 (SbCHS, Scutellaria baicalensis, DNA):
[0223] atggttactgttgaagaatttcatagagctactagagctgaaggtcctgctactgttttggctattggtactgctaatccaccaaattgtgttgaacaatctacttatgctgatta
[0224] ctatttcagaatatgcaaatctgaacatctgactgatttgaaaaagaaattctcaagaatgtgtgaaaaatctggtatcaaaaaaagatacatgcacttgacagaggaattct
[0225] taaaagaaaatgataattttactgcttatgaagctccatctttggatgctagacaagatattgttgttgttgaaattccaaaattgggtaaagaagctgctcaaaaagctattaa
[0226] agaatggggtcaaccaaaatctaaaattactcatgttattttttgtactacttctggtgttgatatgcctggtgctgattatcaaattactaaattgttgggtttgagaccatctgtt
[0227] aagagattcatgatgtatcaacaaggttgttttgctggtggtactgttttgagaatggctaaagatttggctgaaaataatgctggtgctagagttttggttgtttgttctgaaat
[0228] tactgctattacttttagaggtccatctgatactcatttggattctttggttggtcaagctttgtttggtgatggtgctggtgctgttattgttggttctgatccaattgttggtgttg
[0229] aaagaccattgtttcaattggtttctgctgctcaaactattttgcctgattctgaaggtgctattgatggtcatgttagagaagttggtttgacattccatctgttaaaggatgttc
[0230] ctggtctaatttctaaaaatattgaaaaatctttgaaagaagcttttgctccattgggtatttctgattggaattctttgttttggattgttcatcctggtggtcctgctattttggatc
[0231] aagttgaagaaaaattgggtttgaaacctgaaattatggttccaactagacatgttttgtctgaatatggtaatatgtcttctgcttgtgttttgtttgttatggatgaaatgagaa
[0232] aagcttctgctaaagatggttgtactactactggtgaaggtaaagattggggagttttgtttggttttggtcctggtttgactgttgaaactgttgttttgcattctgttccattga
[0233] attga
[0234] SEQ ID NO:4 (SbCHI, Scutellaria baicalensis, DNA):
[0235] atgtctgcttctccatctgttactaaagttttggttgaatctattgaattttctcctgctgctaaaccacctggttcttctaatactttgtttttgggtggtgctggtgttagaggtat
[0236] ggaaattcaaggtaattttgttaaatttactgctattggtgtttatttggaagattctgctgttccatctttggctgttaattggaaaggtaaaactgctgaagaattgactgagtc
[0237] tgatgatttttttagagaaattgtttctggtccatttgaaaaatttactaaagttactatgattttgccattgactggtaaacaatattctgaaaaagttgctgaaaattgtgttgctt
[0238] attggaaagctgttggtaaatatactgatgctgaatctgaagctattgataaatttttgcaagtttttaaagatgaaacttttgctcctggtgcttctattttgtttactcaatctcct
[0239] gctggttctttgactatttctttttctaaagatggttctattcctgaacaaggtaaagctgttattgaaaataaacaattgtctgaagctgttttggaatctattattggtaaacatg
[0240] gtgtttctccatctgctaaacaatctttggctgctagattgtctgaattgttttga
[0241] SEQ ID NO:5 (PcFNSI, parsley, DNA)
[0242] atggccccgactacaatcacggcactggccaaagaaaaaactttgaacctagatttcgttcgcgatgaagatgaacggccgaaagtcgcctataatcagttttcaaatga
[0243] gataccaattattagcttagctggtcttgatgatgatagtgacgggagacgtcctgaaatttgtcgtaagatagtcaaagcatgcgaggattggggcatcttccaggttgta
[0244] gatcatggtatcgactcaggtttaatatccgagatgactcgcctctctcgtgaatttttcgctctgccggcggaagaaaagcttgagtacgacaccaccggaggtaaacga
[0245] gggggcttcacaatctcgacggtcctacaaggcgacgacgcaatggactggcgcgagtttgtaacctatttttcctatcccataaacgcgcgagattactcgaggtggcc
[0246] gaagaaacccgagggatggcgttctactacagaagtatactccgaaaagctgatggttttaggtgctaagctattggaagtattgagcgaggcgatgggattggagaaa
[0247] ggtgaccttacgaaagcgtgcgtagatatggaacagaaggtgctgattaattattatcctacctgtccacagcctgaccttacgttgggggttagacggcacactgatcca
[0248] ggaacaataactattctcctccaggacatggtgggaggtttacaagccacccgggatggcgggaaaacttggataacagtgcaacctgtcgaaggcgctttcgtagtta
[0249] atctgggggaccacgggcattacttatctaacggacgctttcgtaatgctgaccaccaagcagtggttaacagcacctctagtaggctaagtattgcgacattccaaaatc
[0250] cagcccaaaacgcaatcgtctatccccttaagatcagggaaggcgaaaaagccatccttgatgaggctattacctacgcagaaatgtacaagaagtgtatgacgaagca
[0251] tatagaggtggctactcgtaaaaagttggcgaaagagaagagactccaggacgagaaagcgaaattagagatgaagtcaaaatctgcagatgaaaatctcgcctga
[0252] SEQ ID NO:6 (OsF3’H, rice, DNA):
[0253] atggacgtcgtcccattgccattgcttttgggttctttggcagtttcagcagcagtttggtacttggtctacttcttgagaggcggttccggaggagacgcagctagaaaaa
[0254] gaagaccattgccaccaggtccaagaggttggccagtattgggtaacttgccacagttgggagacaagccacatcacactatgtgcgctttggctagacagtacggtcc
[0255] attgttcaggttgaggttcggttgcgcagaagttgttgttgcagcatcagctccagttgcagctcaatttttgagaggccacgacgctaacttctccaatagaccaccaaatt
[0256] ccggcgcagaacacgttgcttacaactaccaagacttggttttcgctccatacggcgctagatggagagccttgagaaagctttgcgctttgcacttgttctccgctaagg
[0257] ctttggacgacttgagagcagttagagaaggcgaagttgccttgatggtgagaaacttggccagacaacaagccgcttcagttgctttgggtcaagaagccaacgtttgc
[0258] gctaccaacactttggctagagctaccatcggtcacagagttttcgcagttgacggaggagaaggagctagagaattcaaggagatggtcgtcgagttgatgcagttgg
[0259] caggcgttttcaacgttggcgatttcgttccagcattgaggtggttggatccacaaggcgttgttgccaagatgaagagattgcacaggaggtacgacaacatgatgaac
[0260] ggcttcatcaacgaaagaaaggccggagctcaaccagatggtgttgcagcaggagaacacggtaacgatttgttgagcgtgttgttggccaggatgcaagaagaacaa
[0261] aagttggacggcgacggagaaaagatcaccgaaaccgacatcaaggccttgttgttgaacttgttcaccgccggtaccgatactacttcttctaccgtcgagtgggcttt
[0262] ggcagaattgatcaggcatccagacgtcttgaaggaggctcaacacgaattggacaccgtcgttggtagaggtagattggtttctgaatccgacttgccaagattgccat
[0263] acttgaccgccgttatcaaggaaacttttagattgcacccatccactccattgtccttgccaagagaagcagcagaagagtgcgaagttgacggttacagaatcccaaag
[0264] ggcgctactttgttggtcaacgtttgggccatcgctagagatccaactcagtggccagatccattgcaataccaaccatccagattcttgccaggtagaatgcacgcaga
[0265] cgttgacgttaaaggcgcagatttcggtttgatcccatttggcgccggtagaaggatttgcgccggtttatcttggggtttgagaatggtcactttgatgaccgctaccttgg
[0266] ttcacggtttcgattggactttggctaacggagctactccagacaagttgaacatggaggaggcttacggtttgaccttgcaaagagccgttccattgatggtccaaccag
[0267] tcccaaggttgttgccatccgcctacggagtttga
[0268] SEQ ID NO:7 (AtCPR1, Aspergillus terreus, DNA)
[0269]
[0270] SEQ ID NO:8 (TcCGT1, Trollius chinensis, DNA)
[0271] atggagaagtccaacccaaactccacttccaagccacacgtcttcttgttggcttctccaggtatgggtcacttgatcccattcttggagttgagcaagaggttggtcaccttga
[0272] acaccttgcaggtcaccttgttcatcgtctccaacgaagctaccaaggctagatcccacttgatggaatcctccaacaacttccacccagacttggagttggtcgatttgacac
[0273] cagccaacttgtccgaattgttgtctaccgacgctaccgttttcaagaggatcttcctaatcacccaggccgctatcaaggatttggagtccaggatctcctctatgtctactcca
[0274] ccagccgctttgatcgttgacgttttctccatggacgcctttccagttgccgataggttcggcatcaagaagtacgtcttcgtcaccttgaacgcttggttcttggctttgaccacc
[0275] tacgttaggaccttggatagggaaatcgaaggcgaatacgtcgacttgccagaaccaattgccattccaggttgcaagccattaagaccagaagacgtcttcgatccaatgtt
[0276] gtccaggtcttccgacggttacagaccatacttgggcatgtccgaaagattgaccaaggcagacggcttgttgttgaacacttgggaagccttggaaccagttagcttgaagg
[0277] ctttgagggagaacgagaagttgaaccagatcatgaccccaccattgtatccagttggtccagttgctagaaccaccgttcaagaagtcgtcggtaacgagtgcttggattgg
[0278] cttagcaagcaaccaaccgagtccgttttgtacgttgctttgggttccggcggtattatctcctacaagcaaatgaccgagttggcttggggtctagaaatgtcaaggcagagg
[0279] ttcatttgggtcgtcagattgccaaccatggaaaaggacggagcttgcagattcttctccgacgtcaacgtcaagggtccattggaatacttgccagagggtttcctagacagg
[0280] aacaaggagttgggtatggtgttgccaaattggggtccacaagacgctatcttggctcatccatctaccggaggtttcttgtctcattgcggttggaactcctccttggaatccat
[0281] cgtcaacggcgttccagttattgcttggccattgtacgccgaacagaagatgaacgctaccttgttgaccgaagaattgggcgttgccgttagaccagaagttttgccaacca
[0282] aggccgttgtttccagagacgaaatcgagaagatggtcaggagagtcatcgaatccaaggagggcaagatgaagaggaacagagctagatccgtccaatccgacgctttg
[0283] aaggctatcgaaaaaggcggttcctcctacaacaccttgatcgaagtcgctaaggagttcgagaagaaccacaaggtcttgtga
[0284] SEQ ID NO:9 (ScGAL10, Saccharomyces cerevisiae, DNA)
[0285] atgacagctcagttacaaagtgaaagtacttctaaaattgttttggttacaggtggtgctggatacattggttcacacactgtggtagagctaattgagaatggatatgactgtgtt
[0286] gttgctgataacctgtcgaattcaacttatgattctgtagccaggttagaggtcttgaccaagcatcacattcccttctatgaggttgatttgtgtgaccgaaaaggtctggaaaa
[0287] ggttttcaaagaatataaaattgattcggtaattcactttgctggtttaaaggctgtaggtgaatctacacaaatcccgctgagatactatcacaataacattttgggaactgtcgtt
[0288] ttattagagttaatgcaacaatacaacgtttccaaatttgttttttcatcttctgctactgtctatggtgatgctacgagattcccaaatatgattcctatcccagaagaatgtccctta
[0289] gggcctaataatccgtatggtcatacgaaatacgccattgagaatatcttgaatgatctttacaatagcgacaaaaaaggttggaagtttgctatcttgcgttattttaacccaatt
[0290] ggcgcacatccctctggattaatcggagaagatccgctaggtataccaaacaatttgttgccatatatggctcaagtagctgttggtaggcgcgagaagctttacatcttcgga
[0291] gacgattatgattccagagatggtaccccgatcagggattatatccacgtagttgatctagcaaaaggtcatattgcagccctgaaatacctagaggcctacaatgaaaatgaa
[0292] ggtttgtgtcgtgagtggaacttgggttccggtaaaggttctacagtttttgaagtttatcatgcattctgcaaagcttctggtattgatcttccatacaaagttacgggcagaaga
[0293] gcaggtgatgttttgaacttgacggctaaaccagatagggccaaacgcgaactgaaatggcagaccgagttgcaggttgaagactcctgcaaggatttatggaaatggacta
[0294] ctgagaatccttttggttaccagttaaggggtgtcgaggccagattttccgctgaagatatgcgttatgacgcaagatttgtgactattggtgccggcaccagatttcaagccac
[0295] gtttgccaatttgggcgccagcattgttgacctgaaagtgaacggacaatcagttgttcttggctatgaaaatgaggaagggtatttgaatcctgatagtgcttatataggcgcc
[0296] acgatcggcaggtatgctaatcgtatttcgaagggtaagtttagtttatgcaacaaagactatcagttaaccgttaataacggcgttaatgcgaatcatagtagtatcggttctttc
[0297] cacagaaaaagatttttgggacccatcattcaaaatccttcaaaggatgtttttaccgccgagtacatgctgatagataatgagaaggacaccgaatttccaggtgatctattgg
[0298] taaccatacagtatactgtgaacgttgcccaaaaaagtttggaaatcgtatataaaggtaaattgactgctggtgaagcgacaccaataaatttaacaaatcatagttatttcaat
[0299] ctgaacaagccatatggagacactattgagggtacggagattatggtgcgttcgaaaaaatctgttgatgtcgacaaaaacatgattcctacgggtaatatcgtcgatagaga
[0300] aattgctacctttaactctacaaagccaacggtcttaggccccaaaaatccccagtttgatggttgttttgtggtggatgaaaatgctaaaccaagtcaaatcaatactctaaaca
[0301] atgaattgacgcttattgtcaaggcttttcatcccgattccaatattacattagaagttttaagtacagagccaacttatcaattttacaccggtgatttcttgtctgctggttacgaag
[0302] caagacaaggttttgcaatcgagcctggtagatacattgatgctatcaatcaagagaactggaaagattgtgtaaccttgaaaaacggtgaaacttacgggtccaagattgtct
[0303] acagattttcctga
[0304] SEQ ID NO:10 (TcOGT4, Trollius chinensis, DNA):
[0305] atggttattatgacccaaaccccagccgcagttgttgttcacgttgccatgttcccttggttcgctatgggtcatatcggcccttacttgcagatcgctaacaagttcgccgaaag
[0306] aggtcacagagtctccttcttcgtcccattgaagaccaaggacaaggtcaagcacttgaacttgcacccacacttgatccacttcatcccaatcaccatgccacaagttgacg
[0307] gtttaccaccaggagttgaaactacagcagacgcagcagctcatttggctccattgatctccgttgccttcgattccacccaagatcagttgtccttgtccttgcagtccttgaag
[0308] ccagacgttgtcttctacgacttctcccattggttgccatccttggcaagaccattgggtatcaagccagtctacttcgctatgtcttccgcagtttctcacgctttgttgttggtccc
[0309] atccaggaagaagcagatgacctccgtcatcgacttgagagaaccaccaccaggtttcccatcttcttcttccatcatgcaccaaaggccattcgaagctagagacgagattt
[0310] ggttctccagcgaattccacggtaggatgtccttctacgacaggttgacctcttgcatcagagaaggagacgcagcttgtttcagagcttgccacgaaatcgaaggtcctttct
[0311] gcgactacgtttccaaccagtacgacaacaagccagtcttgttgatgggcgcagttttgccagaagctaccactaccatcaagttggaggagaagtgggagaagtggttagg
[0312] aggtttcgagaagggttccgttgtttattgcgccttcggtagcgagtgcgaattgaagaaggagcaattccaggagttggtgttgggtttggagttgaccggtttgcctttcttg
[0313] gtgagattgtccccaccaatgggttgtaagaccgttgaagaggctttgccagaaggtttcgaggaaagagtcagaggtagaggagttgttcacggaggttggatgcagcaa
[0314] cagttgatcttgtcccacccatccgttggttgtttcgtttcccattccggtccagcttctatttgggaagccttggttagcgacgcccaaattgttgtcgtcccatacagaggtgac
[0315] caattcgttgtcgccaagttcgttgccagagaaatcaagatcggcgtcgaagttgagaggagagaagaagacggttggtacactagggaagacgtttgcaaggtcttgaag
[0316] gtcgtcatggaccaaggttctcaagttggcgatcaggttagagctaaccaccagaagtggaaggacttcttgttgaccccaggtttggacaaggcctacttcgacaacttcat
[0317] catcaagctacaggacttgatcaactccaagtga
[0318] SEQ ID NO:11:gaccttcgtttgtgcggatcagatcttttttgtagaaatgtc
[0319] SEQ ID NO:12:gctatggtgtgtgggggatcctctcacttaatcttctgtac
[0320] SEQ ID NO:13:gaagattaagtgagaggatcatcagatcttttttgtagaaatgtc
[0321] SEQ ID NO:14:ggcagtaattgatatactagattttggtcatgcatgagat
[0322] SEQ ID NO:15:gacctaccctacgacgggccttgaagctatggtgtgtggg
Claims
1. A method for producing flavonoid glycosides, It is characterized in that The method comprises: providing a yeast engineering bacterium, introducing a naringenin synthesis module into the yeast engineering bacterium to synthesize naringenin; and further comprising: (a) introducing the expression cassette of the following enzymes: FNSI, F3'H, CPR1, CGT1, so as to synthesize orientin using naringenin as a precursor; or (b) Introducing the expression cassettes of the following enzymes: FNSI, CGT1, thereby synthesizing vitexin using naringenin as a precursor.
2. The method according to claim 1, It is characterized in that (a) further comprises an expression cassette for introducing the following enzymes: GAL10, OGT4, so as to synthesize orientin 2″-O-galactoside using orientin as a precursor; or (b) further comprises an expression cassette for introducing the following enzymes: GAL10, OGT4, so as to synthesize vitexin 2″-O-galactoside using vitexin as a precursor; Preferably, the naringenin synthesis module comprises expression cassettes of the following enzymes: TAL, 4CL, CHS, CHI.
3. The method according to any one of claims 1 to 2, It is characterized in that The yeast engineering bacteria are cultured using yeast culture medium, preferably a carbon source is added during the culture period; preferably, the carbon source is glucose and / or ethanol; Preferably, when producing vitexin, orientin, vitexin 2″-O-galactoside or orientin 2″-O-galactoside, no precursor amino acids and / or flavonoids and / or malonyl-CoA and / or UDP-glucose are added.
4. A yeast engineered bacterium for producing flavonoid glycoside compounds, wherein the yeast engineered bacterium comprises a naringenin synthesis module and an expression cassette selected from (a) or (b): (a) an expression cassette of the following enzymes: FNSI, F3'H, CPR1, CGT1, wherein the expression cassette uses naringenin as a precursor to synthesize orientin; or (b) Expression cassettes of the following enzymes: FNSI, CGT1, which synthesize vitexin using naringenin as a precursor.
5. The yeast engineering bacteria according to claim 4, It is characterized in that (a) further comprises the expression cassette of the following enzymes: GAL10, OGT4, wherein the expression cassette uses orientin as a precursor to synthesize orientin 2″-O-galactoside; or (b) further comprises an expression cassette of the following enzymes: GAL10, OGT4, wherein the expression cassette uses vitexin as a precursor to synthesize vitexin 2″-O-galactoside; Preferably, the naringenin synthesis module comprises expression cassettes of the following enzymes: TAL, 4CL, CHS, CHI.
6. The method according to any one of claims 1 to 3 or the engineered yeast according to any one of claims 4 to 5, It is characterized in that The GAL10 is from Saccharomyces cerevisiae (Sc); The OGT4 and CGT1 are from Trollius chinensis (Tc); The F3'H is from rice (Oryza sativa; Os); The CPR1 is from Aspergillus terreus (At); The FNSI is derived from parsley (Petroselinum crispum; Pc); The TAL is from Flavobacterium johnsoniaeu (Fj); The 4CL, CHS and CHI are from Scutellaria baicalensis Georgi (Sb).
7. A method for adding a sugar group to the sugar group of vitexin or orientin, It is characterized in that The method comprises: using vitexin or orientin as a precursor, and using two enzymes, GAL10 and OGT4, to perform a catalytic reaction, thereby making vitexin form vitexin 2"-O-galactoside, or making orientin form orientin 2"-O-galactoside.
8. Use of gene combinations for producing or modifying flavonoid glycosides; in, The gene combination is gene combination a, which is a combination of GAL10 and OGT4, and is used to add a sugar group to the sugar group of vitexin or orientin; preferably, the gene combination 1 causes vitexin to form vitexin 2"-O-galactoside, or causes orientin to form orientin 2"-O-galactoside.
9. Use of gene combinations for producing or modifying flavonoid glycosides; in, The gene combination is gene combination b, which includes a combination of FNSI, F3'H, CPR1 and CGT1, and is used to synthesize orientin using naringenin as a precursor; or it includes a combination of TAL, 4CL, CHS, CHI, FNSI, F3'H, CPR1 and CGT1, and is used to synthesize orientin from scratch; or The gene combination is gene combination c, which is a combination of FNSI and CGT1, used to synthesize vitexin using naringenin as a precursor; or a combination thereof including TAL, 4CL, CHS, CHI, FNSI and CGT1, used to synthesize vitexin from scratch; or The gene combination is gene combination d, which is a combination of FNSI, F3'H, CPR1, CGT1, GAL10 and OGT4, and is used to synthesize orientin 2"-O-galactoside using naringenin as a precursor; or a combination of TAL, 4CL, CHS, CHI, FNSI, F3'H, CPR1, CGT1, GAL10 and OGT4, and is used to synthesize orientin 2"-O-galactoside from scratch; or The gene combination is gene combination e, which is a combination of FNSI, CGT1, GAL10 and OGT4, and is used to synthesize vitexin 2"-O-galactoside using naringenin as a precursor; or a combination thereof including TAL, 4CL, CHS, CHI, FNSI, CGT1, GAL10 and OGT4, and is used to synthesize vitexin 2"-O-galactoside from scratch.
10. A kit for producing or modifying flavonoid glycoside compounds, wherein include: The engineered yeast according to claim 4 or 5; or One or more gene combinations as defined in claim 8 or 9; Preferably, the gene combination is contained in an expression cassette or expression construct; Preferably, the kit further comprises: glucose and / or ethanol.
